Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Announces Clearance

of IND for TNX-102 SL for Treatment of Alcohol Use Disorder

2020 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today

announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation

of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD). The program in AUD is expected

to qualify for the 505(b)(2) pathyway for FDA approval.

"We are excited to have received the FDA's IND clearance

to begin clinical trials for TNX-102 SL in AUD," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "An estimated

36 million adults in the United States have AUD, a chronic relapsing brain disease characterized by compulsive alcohol use, loss

of control over alcohol intake, and, very commonly, sleep disturbances which significantly impact cognition, mood and the ability

to recover. We believe that by improving sleep quality, the mechanism of action of TNX-102 SL, the rate of successful recovery

for people with AUD after detox can be improved."

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering,

licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's

portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes

vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio

includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead

vaccine candidate, TNX-1800*, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19,

primarily by eliciting a T cell response. Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year.

TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox

and serves as the vector platform on which TNX-1800 is based. Tonix is also developing TNX-2300*, a second live replicating vaccine

candidate for the prevention of COVID-19, but using bovine parainfluenza as the vector. Tonix's lead CNS candidate, TNX-102

SL**, is in Phase 3 development for the management of fibromyalgia. The Company expects results from an unblinded interim analysis

in September 2020 and topline data in the fourth quarter of 2020. TNX-102 SL is also in development for agitation in Alzheimer's

disease and alcohol use disorder (AUD). The agitation in Alzheimer's disease program is Phase 2 ready with FDA Fast Track

designation, and the development program for AUD is now also Phase 2 ready. Tonix's programs for treating addiction conditions

also include TNX-1300* (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution), which is in Phase 2 development for

the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation. TNX-601 CR** (tianeptine oxalate

controlled-release tablets) is another CNS program, currently in Phase 1 development as a daytime treatment for depression while

TNX-1900**, intranasal oxytocin, is in development as a non-addictive treatment for migraine and cranio-facial pain. Tonix's

preclinical pipeline includes TNX-1600** (triple reuptake inhibitor) , a new molecular entity being developed as a treatment for

PTSD; TNX-1500* (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune

conditions; and TNX-1700* (rTFF2), a biologic being developed to treat gastric and pancreatic cancers.

*TNX-1800, TNX-801, TNX-2300, TNX-1300, TNX-1500 and TNX-1700 are

investigational new biologics and have not been approved for any indication.

**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900 are investigational

new drugs and have not been approved for any indication.

This press release and further information

about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within

the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking

words such as "anticipate," "believe," "forecast," "estimate," "expect,"

and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual

results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated

by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances

or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related

to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties

of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development

efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are

significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation

to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form

10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the "SEC") on March

24, 2020, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements

are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only

as of the date thereof.

Jessica Morris (corporate)

Tonix Pharmaceuticals

Travis Kruse (media)

Peter Vozzo (investors)